कर्नाटका एन्टिबायोटिक्स एण्ड फार्मास्युटिकल्स लिमिटेड
(भारत सरकार का उद्यम)
KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LIMITED
(A Government of India Enterprise)

ENQUIRY REF No:	KAPL/QAD/020/2145
DATE	20.02.2026
DUE DATE	26.02.2026 (13:00HRS)

Dear Sir,

Please submit your lowest and competitive offer in a SEALED ENVELOPE, DULY SUPERSCRIBING OUR ABOVE ENQUIRY REF. NO., DATE and DUE DATE on it/ OR MAIL, with other details of F.O.R terms, Taxes, Credit period, Delivery offered, Name of the Make, Detailed Specification etc., for below mentioned material/s

SL NO.	ITEM CODE	ITEM DESCRIPTION	UOM	QTY
01	QSPDP3CLM	25 CM X 4.6MM 5 MICRON ODS LICHROSPHERE RP-18	NOS	01

1) Please ensure that your offer reaches us on or before Due Date by courier OR speed post Or you can also mail us to our email: purenp@kaplindia.com
2) Please send your quotation mentioning item code

OTHER TERMS:

1. F.O.R TERMS : DOOR DELIVERY TO PEENYA FACTORY
2. GST % : PLEASE SPECIFY
3. PACKING & FORWARDING CHARGES : NOT APPLICABLE
4. CREDIT PERIOD : 30 DAYS
5. DELIVERY OFFERED :
6. ATTACHED PAGES : 02

NOTE: IN CASE YOU ARE NOT QUOTING PLEASE SEND THE REGRET LETTER.

Thanking you,

Yours faithfully,
For KARNATAKA ANTIBIOTICS
& PHARMACEUTICALS LIMITED

YUVARAJA M
DEPUTY MANAGER PURCHASE DEPT

User Requirement specifications

Material Description : HPLC COLUMN 25 cm x 4.6mm, 5µm (ODS) Lichrosphere RP-18
URS Number: QC/URS/02/02/26

1. Description and Quantity:

Material Description	25cm x 4.6mm, 5 µm (ODS) Lichrosphere RP-18
Item code	QSDP3CLM
Quantity/ Box	1

2. User Specifications:

#	Requirement	Specification
1	Name	25cm x 4.6mm, 5um
2	Matrix active group	octadecylsilane RP-18
3	Particle size	5u
4	Length (mm)	250
5	Internal Diameter (I.D.)	4.6 mm
6	Particle type	Base-Deactivated Silica
7	Particle Shape	Spherical
8	External Construction Materials	Stainless Steel
9	Endcapped	Yes
10	USP Classification	L1
11	Separation Mode	Reverse phase
12	P^H Range	2-8
13	Maximum Pressure	6000 psi (410 Bar)
14	Pore Size	100 °A

procedure for removal of bacterial endotoxins complies with the following additional requirement.

Bacterial endotoxins (2.2.3). Not more than 0.20 Endotoxin Unit per mg of ceftriaxone sodium.

Ceftriaxone Sodium intended for use in the manufacture of parenteral preparations without a further appropriate sterilisation procedure complies with following requirement.

Sterility (2.2.11). Complies with the test for sterility.

Storage. Store protected from light and moisture.

Labelling. The label states, where applicable, that the substance is free from bacterial endotoxins.

Ceftriaxone Injection

Ceftriaxone Injection is a sterile material consisting of Ceftriaxone Sodium with or without excipients. It is filled in a sealed container.

The injection is constituted by dissolving the contents of the sealed container in the requisite amount of sterile Water for Injections, immediately before use.

The constituted solution complies with the requirements for Clarity of solution and Particulate matter stated under Parenteral Preparations (Injections).

Usual strengths. The equivalent of 250 mg; 500 mg; 1 g and 2 g of ceftriaxone.

Storage. The constituted solution should be used immediately after preparation but, in any case, within the period recommended by the manufacturer.

Ceftriaxone Injection contains not less than 90.0 per cent and not more than 115.0 per cent of the stated amount of ceftriaxone, $C_{18}H_{18}N_8O_7S_3$.

Description. A white or almost white powder.

The contents of the sealed container comply with the requirements stated under Parenteral Preparations (Powders for Injection) and with the following requirements.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with *ceftriaxone sodium IPRS* or with the reference spectrum of ceftriaxone sodium.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution (a).

C. It gives the reaction A of sodium salts (2.3.1).

Tests

Appearance of solution. A 1.2 per cent w/v solution in *carbon dioxide-free water* is clear (2.4.1) and not more intensely coloured than reference solution BYS5 or YS5 (2.4.1).

pH (2.4.24). 6.0 to 8.0, determined in a 10.0 per cent w/v solution.

Related substances. Determine by liquid chromatography (2.4.14).

Test solution. Dissolve a quantity of injection containing 30 mg of ceftriaxone in the mobile phase and dilute to 100.0 ml with the mobile phase.

Reference solution (a). A 0.03 per cent w/v solution of *ceftriaxone sodium IPRS* in the mobile phase.

Reference solution (b). A solution containing 0.005 per cent w/v, each of, *ceftriaxone sodium IPRS* and *ceftriaxone sodium E-isomer IPRS* in the mobile phase.

Reference solution (c). Dilute 1.0 ml of reference solution (a) to 100.0 ml with the mobile phase.

Chromatographic system

- a stainless steel column 25 cm × 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm) (Such as Lichrosphere RP-18),
- mobile phase: dissolve 2 g of *tetradecylammonium bromide* and 2 g of *tetraheptylammonium bromide* in a mixture of 440 ml of *water*, 55 ml of *0.067 M mixed phosphate buffer pH 7.0*, 5 ml of a buffer prepared by dissolving 20.17 g of *citric acid* in 800 ml of *water*, adjusted to pH 5.0 with *10 M sodium hydroxide* and diluting to 1000 ml with *water*, and 500 ml of *acetonitrile*,
- flow rate: 1.5 ml per minute,
- spectrophotometer set at 254 nm,
- injection volume: 20 µl.

Inject reference solution (b). The test is not valid unless the resolution between the two principal peaks is at least 3.0.

Inject reference solution (c) and the test solution. Run the chromatogram at least twice the retention time of the principal peak. In the chromatogram obtained with the test solution the area of any secondary peak is not greater than the area of the principal peak in the chromatogram obtained with reference solution (c) (1.0 per cent) and the sum of the areas of all the secondary peaks is not greater than 5 times the area of the principal peak in the chromatogram obtained with reference solution (c) (5.0 per cent). Ignore any peak with an area less than 0.1 times the area of the principal peak in the chromatogram obtained with reference solution (c) (0.1 per cent).

Bacterial endotoxins (2.2.3). Not more than 0.2 Endotoxin Unit per mg of ceftriaxone.

Water (2.3.43). Not more than 11.0 per cent, determined on 0.1 g.